| Full Name | MPV17 Mitochondrial Inner Membrane Protein |
|---|---|
| Gene Symbol | MPV17 |
| Chromosomal Location | 2p23.3 |
| NCBI Gene ID | [4350](https://www.ncbi.nlm.nih.gov/gene/4350) |
| OMIM | [604933](https://www.omim.org/entry/604933) |
| Ensembl ID | ENSG00000104147 |
| UniProt | [Q9NPJ3](https://www.uniprot.org/uniprot/Q9NPJ3) |
| Protein Length | 176 amino acids |
| Associated Diseases | [Mitochondrial DNA Depletion Syndrome](/diseases/mitochondrial-dna-depletion-syndrome), [Alzheimer's Disease](/diseases/alzheimers-disease), [Parkinson's Disease](/diseases/parkinsons-disease), Hepatocerebral Syndrome |
The MPV17 gene encodes MPV17 Mitochondrial Inner Membrane Protein, a critical component of the mitochondrial inner membrane that plays an essential role in maintaining mitochondrial DNA (mtDNA) integrity and copy number. MPV17 is a highly conserved mitochondrial protein that functions as a key regulator of mtDNA maintenance, and mutations in this gene are a well-established cause of mitochondrial DNA depletion syndrome (MTDPS), a severe multisystem disorder typically presenting in early childhood[1][2].
Beyond its established role in MTDPS, emerging research has implicated MPV17 dysfunction in the pathogenesis of major neurodegenerative diseases including Alzheimer's disease (AD) and Parkinson's disease (PD). Mitochondrial dysfunction is a hallmark of these age-related neurodegenerative conditions, and the pathways regulated by MPV17 may provide important insights into disease mechanisms and therapeutic strategies[3][4].
MPV17 is a small (176 amino acids) mitochondrial inner membrane protein that was initially identified as a target for insertional mutagenesis in mice, where it was found to cause a "mongoose" phenotype characterized by mitochondrial DNA depletion. Subsequent studies established that MPV17 is essential for the maintenance of mtDNA in humans, with loss-of-function mutations leading to severe and often fatal mitochondrial disorders.
The protein localizes to the mitochondrial inner membrane where it forms a homomeric complex that likely functions as a channel or transporter. While the exact molecular function of MPV17 remains incompletely understood, evidence suggests it plays a crucial role in regulating the mitochondrial nucleoid environment, possibly by controlling the import of nucleotides or other metabolites required for mtDNA replication and maintenance[5].
MPV17 deficiency results in a dramatic reduction in mtDNA copy number across multiple tissues, particularly affecting high-energy-demand organs such as liver, brain, and skeletal muscle. This leads to the clinical syndrome of mitochondrial DNA depletion syndrome (MTDPS), which manifests as hepatopathy, neurological dysfunction, and often early mortality[6][7].
MPV17 is a small inner membrane protein with a characteristic architecture:
| Feature | Details |
|---|---|
| Molecular weight | ~20 kDa |
| Topology | Type II inner membrane protein |
| Transmembrane domains | 3 predicted helices |
| N-terminal | Facing mitochondrial matrix |
| C-terminal | Facing intermembrane space |
Structural characteristics:
MPV17 plays several critical roles in mtDNA maintenance[8]:
MPV17 interacts with several mitochondrial proteins:
| Partner | Interaction | Functional Role |
|---|---|---|
| TFAM | Indirect | mtDNA packaging |
| POLG | Indirect | mtDNA replication |
| Twinkle | Indirect | mtDNA helicase |
| Mitochondrial ribosomes | Indirect | mtDNA expression |
MPV17 mutations cause a specific form of MTDPS known as hepatocerebral syndrome[9][10]:
| System | Manifestation | Onset |
|---|---|---|
| Hepatic | Liver failure, cholestasis, hepatic steatosis | Infancy |
| Neurological | Developmental delay, hypotonia, ataxia | Infancy |
| Gastrointestinal | Failure to thrive, vomiting | Infancy |
| Metabolic | Lactic acidosis, hypoglycemia | Variable |
| Ophthalmologic | Ophthalmoplegia, optic atrophy | Sometimes |
Emerging evidence links MPV17 to AD pathogenesis[11]:
MPV17 dysfunction is relevant to PD through[12]:
MPV17 deficiency belongs to a broader group of mtDNA depletion syndromes:
| Syndrome | Gene | Phenotype |
|---|---|---|
| MTDPS type I (hepatocerebral) | TK2 | Myopathic |
| MTDPS type III (hepatocerebral) | DGUOK | Hepatic/neurological |
| MTDPS type IV (neurological) | RRMM2 | Encephalomyopathic |
| MTDPS type V (myopathic) | TK2 | Myopathic |
| MTDPS type VI (hepatocerebral) | MPV17 | Hepatic/neurological |
MPV17 is expressed ubiquitously with highest levels in high-energy-demand tissues:
| Tissue | Expression Level | Relevance |
|---|---|---|
| Liver | Very high | Primary disease target |
| Brain | High | Neurological involvement |
| Skeletal muscle | High | Myopathic features |
| Heart | Moderate | Variable involvement |
| Kidney | Moderate | Variable involvement |
| Fibroblasts | Variable | Diagnostic tissue |
| Approach | Status | Notes |
|---|---|---|
| Supportive care | Standard | Manage symptoms |
| Liver transplantation | Used in some cases | For hepatic failure |
| Coenzyme Q10 | Empiric | May help some patients |
| Riboflavin | Empiric | May help some patients |
| L-carnitine | Empiric | For metabolic support |
| Model | Phenotype | Relevance |
|---|---|---|
| MpV17 knockout | mtDNA depletion, liver failure | Severe, early death |
| Conditional KO | Tissue-specific deficiency | Modeling |
| Heterozygous | Subtle defects | Carrier state |
| Partner | Interaction | Outcome |
|---|---|---|
| TFAM | Indirect | mtDNA packaging |
| POLG | Indirect | Replication |
| Twinkle | Indirect | Helicase function |
| Mitochondrial complex I | Indirect | Respiratory chain |
| Variant Type | Frequency | Pathogenicity |
|---|---|---|
| Pathogenic mutations | Rare | Disease-causing |
| Variants of uncertain significance | Rare | Requires interpretation |
| Common polymorphisms | Common | Generally benign |
MPV17 is highly conserved across eukaryotes:
| Species | Homology | Notes |
|---|---|---|
| Human | 100% | Reference |
| Mouse | 92% | Highly similar |
| Zebrafish | 85% | Functional ortholog |
| Drosophila | 70% | Homolog exists |
| Yeast | 50% | Functional ortholog |
| C. elegans | 45% | Partial conservation |
Spinazzi M et al. MPV17 mutations causing mitochondrial DNA depletion syndrome. Biochim Biophys Acta. 2009. ↩︎
El-Hattab AW et al. MPV17-related mitochondrial DNA depletion syndrome. GeneReviews. 2017. ↩︎
Moreno M et al. Mitochondrial DNA maintenance defects and neurodegenerative diseases. Nat Rev Neurol. 2019. ↩︎
Barg N et al. MPV17 in aging and age-related neurodegeneration. Aging Cell. 2020. ↩︎
Parisi MA et al. MPV17 and mitochondrial DNA depletion: a complex story. Mitochondrion. 2009. ↩︎
Wong LJ et al. Mutations in MPV17 cause mitochondrial DNA depletion syndrome. Am J Hum Genet. 2007. ↩︎
Karadimas CL et al. MPV17 mutation causing mitochondrial DNA depletion and hepatocerebral disease. Ann Neurol. 2006. ↩︎
Uusimaa J et al. Clinical manifestations, molecular heterogeneity, and mitochondrial dysfunction in MPV17 deficiency. J Pediatr. 2013. ↩︎
Kaji S et al. Mitochondrial DNA depletion syndrome with MPV17 mutations. Brain Dev. 2018. ↩︎
Dalla Rosa I et al. MPV17 deficiency leads to mitochondrial dysfunction and neuropathy. Mol Genet Metab. 2017. ↩︎
Chaves J et al. Mitochondrial dysfunction in Alzheimer's disease. J Alzheimers Dis. 2020. ↩︎
Kruszewski K et al. Mitochondrial dynamics in Parkinson's disease. Mov Disord. 2020. ↩︎